Although the ultimate curative regimens for HBV are currently unknown, we have assembled an industry-leading portfolio of drug development programs targeting hepatitis B, which we will evaluate to determine the best potential combination approaches for patients.
By building a broad platform of direct antiviral and immune stimulation assets, we aim to optimize HBV combination curative strategies, with the ability to adapt our program focus quickly as the field continues to advance. Our combination approach can simultaneously inhibit viral replication, stimulate the host immune response to HBV and eliminate the reservoir of existing cccDNA.